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Introduction {#sec001}
============

The oncologic risk of ionizing radiation is widely known \[[@pone.0204927.ref001]\]. In 1922, bone sarcomas developing after radiotherapy in patients with benign conditions were reported as one of the first solid malignant tumors related to radiotherapy, which implicate radiation treatment as one of the pathogeneses of sarcomas \[[@pone.0204927.ref002]\]. In 1948, 11 cases of post-radiation osteosarcoma (PRS) were first reported in the English literature \[[@pone.0204927.ref003]\]. A recent analysis of the Surveillance, Epidemiology, and End Results (SEER) registries demonstrated that the risk of second primary bone sarcoma in patients who had received radiotherapy was increased by 257% compared to that of primary bone sarcoma in the general population \[[@pone.0204927.ref004]\]. PRSs are uncommon, and they account for 0.5--5% of all sarcomas \[[@pone.0204927.ref001], [@pone.0204927.ref005]\]. While the precise incidence is not known, one of the most comprehensive studies demonstrated that the cumulative incidence was estimated to be less than 1% at 15 years after the previous cancer diagnosis \[[@pone.0204927.ref006]\]. However, PRSs are a growing problem and a critical clinical subgroup of sarcomas because rapid advancements in cancer management and screening have increased the number of long-term cancer survivors \[[@pone.0204927.ref001], [@pone.0204927.ref007]\].

The number of cancer patients has been increasing rapidly in Asian countries. Lifestyle changes, urbanization, changes in reproductive patterns, westernized diet and obesity, and increasing lifespans have contributed to the growing incidence of cancer \[[@pone.0204927.ref008]\]. As radiotherapy reduces cancer mortality and recurrence \[[@pone.0204927.ref004]\], it has become one of the most important modalities in the management of various solid cancers \[[@pone.0204927.ref001]\]. In Japan, 726 facilities delivered radiation therapy for 149793 new patients in 2003 \[[@pone.0204927.ref009]\]. The Study on the Current Status of Radiotherapy in Korea has reported that the number of patients who underwent radiation treatment increased by 65% from 37215 among 154552 cancer patients in 2006 to 56850 among 224177 cancer patients in 2013 \[[@pone.0204927.ref010]\]. In spite of such a situation, scarce reports on PRSs in an Asian population have been published to date. We performed a retrospective multi-national, multi-institutional study to investigate the clinicopathological feature, and prognostic factors of PRSs in an Asian population.

Materials and methods {#sec002}
=====================

Cases obtained from 10 tertiary musculoskeletal oncology centers in four nations were retrospectively reviewed. Based on the existing diagnostic criteria for PRS \[[@pone.0204927.ref003], [@pone.0204927.ref011], [@pone.0204927.ref012]\], we included the following subjects: (1) patients with histologically proven sarcoma which developed within the external beam radiotherapy field; (2) a latency period of more than three years between radiation therapy and appearance of sarcoma. Patients with genetic malignancy predisposition syndrome such as familial retinoblastoma, Li-Fraumeni syndrome, or Rothmund-Thomson syndrome, who had secondary sarcomas at sites distant to the radiation field, who received brachytherapy or total-body irradiation, or who had more than one type of malignancy before the development of secondary sarcoma were excluded from this study. This study was approved by the Institutional Review Board of Catholic Medical Center in Korea. Because we conducted a retrospective review and this was a minimal risk study, and we did not collect any personally identifiable information, any informed consents were not collected from participants.

Data on demographics, primary lesion, and secondary sarcoma was collected. With respect to the primary lesion, the location, histological diagnosis and subtype, radiation therapy, and chemotherapy were evaluated. With respect to secondary sarcoma, histological diagnosis including its subtype and grade, main length and volume, the latency period from radiotherapy, surgery and surgical margin, local recurrence, distant metastasis, oncologic outcome, and follow-up period were assessed. Tumor volume was measured as π/6 x (length) x (width) x (height). Follow-up period was defined as the interval from the diagnosis of PRS to death or the last visit.

Latency period was defined as the interval from the start date of radiotherapy for the primary lesion to the date of recognition of secondary sarcoma development. Distinction in the radiation dose and latency period between bone and soft tissue lesions was estimated by normality test and Student's t-test. The differences in metastasis-free survival rate (MFSR) and overall survival rate (OSR) depending on bone and soft tissue sarcomas were estimated using the log-rank test by univariate analysis. OSR and MFSR were defined as the periods from the date of diagnosis of secondary sarcoma to the date of death or last follow-up, and to the date of recognition of distant metastasis. These rates were calculated using Kaplan-Meier survival curves. The influence of potential prognostic factors was evaluated using the log-rank test by univariate analysis. A p-value below 0.05 was considered statistically significant. SPSS 21.0 for Windows (SPSS Corporation, Chicago, IL) was used for statistical analysis.

Results {#sec003}
=======

Patients {#sec004}
--------

Details of the 43 cases are presented in [Table 1](#pone.0204927.t001){ref-type="table"}. Except for one patient with a low-grade tumor (the 10th soft tissue sarcoma case in [Table 1](#pone.0204927.t001){ref-type="table"}), a total of 42 patients with high-grade tumors were analyzed. There were 29 females and 13 males, with a median age of 58.5 years (range, 13--80 years) at the initial diagnosis of high-grade PRS; 23 patients had bone tumors and 19 had soft tissue tumors. All patients underwent external beam radiotherapy for a benign, borderline, or malignant lesion; the most common histological diagnosis of the primary lesion was breast cancer. The median radiation dosage for the primary lesion was 49.7 Gy (range, 12--72 Gy) in 20 patients for whom data was available, and most of them, except for one patient with the lymphoma of bone, received a minimum dose of 30 Gy. Fourteen patients had undergone chemotherapy for their primary tumor with various combinations of chemotherapeutic agents; alkylating anti-neoplastic agents were administered to four of the five patients for whom related details were available. In the other eight patients, it could not be identified whether chemotherapy was administered. The median latency period was 192 months (range, 46--503 months) in 37 patients for whom data was available. There were no significant differences in radiation dose and latency time according to bone or soft tissue sarcoma in patients for whom data was available (p = 0.235, and 0.922). Thirty-three patients had undergone surgery for PRS; surgical margins were wide in 28 patients, marginal in two patients, and intra-lesional in three patients. Among the nine patients who did not undergo surgery, the median age was 74 years (range, 25--80 years), the median main length and volume of the lesion was 8.6 cm (range, 6-17cm) and 151.16 cm^3^ (range, 25.10--1176.75 cm^3^), respectively, and eight patients had bone sarcomas. Among them, only one patient had initial metastasis, and seven patients had lesions in the pelvis and two patients had lesions in the skull. None of the patients had again received radiotherapy for PRS.

10.1371/journal.pone.0204927.t001

###### Patient details.

![](pone.0204927.t001){#pone.0204927.t001g}

                        Primary lesion                   Post-radiation sarcoma                                                                                                          
  --------------------- -------------------------------- ------------------------ ------------------------ ------------------------ ----- ----------------- -------------------- ------- --------------
  Bone sarcoma                                                                                                                                                                           
  1/F/46                Plasmacytoma                     N/A                      No                       OSA                      187   Pelvis            7 x 7 x 8.5          \-      No
  2/M/25                Retinoblastoma                   49.4/26                  No                       OSA                      287   Temporal bone     10 x 6 x 1           \-      No
  3/F/78                Cancer of the buccal mucosa      30                       TGF, CBDCA               OSA                      281   Mandible          4 x 3.7 x 3.5        \-      Resection/W
  4/F/74                Cervical cancer                  70                       N/A                      Leiomyosarcoma of bone   108   Pelvis            6.4 x 7.9 x 8.6      \-      No
  5/F/64                Cervical cancer                  N/A                      N/A                      OSA                      276   Pelvis            5.6 x 4 x 7.1        \+      LSS/W
  6/M/45                Langerhans cell histhiocytosis   N/A                      No                       OSA                      360   Tibia             4.5 x 4.3 x 6.5      \-      LSS/W
  7/F/60                Rectal cancer                    N/A                      Yes                      UPS of bone              204   Femur             2 x 3 x 3            \-      LSS/W
  8/M/60                Prostate cancer                  N/A                      No                       OSA/Osteoblastic         N/A   Pelvis            5 x 10 x 20          \-      LSS/W
  9/F/57                Uterine cancer                   50                       Yes                      OSA/Conventional         N/A   Pelvis            10 x 15 x 15         \-      No
  10/F/46               Uterine cancer                   N/A                      Yes                      OSA/Osteoblastic         N/A   Pelvis            6 x 7 x 17           \-      No
  11/M/75               Prostate cancer                  N/A                      No                       OSA/Chondroblastic       N/A   Pelvis            4 x 8.5 x 8.5        \-      No
  12/F/63               Uterine cancer                   N/A                      No                       OSA/Osteoblastic         N/A   Pelvis            10 x 7 x 22          \-      LSS/W
  13/F/53               Cervical cancer                  N/A                      No                       OSA/Fibroblastic         228   Coccyx            6 x 8 x 11           \-      LSS/W
  14/F/40               GCT of bone                      N/A                      No                       OSA/Fibroblastic         180   Tibia             6 x 7 x 8            \+      LSS/W
  15/F/72               Breast cancer                    50/25                    No                       Chondrosarcoma           192   Humerus           4 x 6 x 6            \+      Amputation/W
  16/F/47               Breast cancer                    N/A                      N/A                      OSA/Chondroblastic       228   Sterum            4 x 5 x 6            \-      Resection/W
  17/F/76               Cervical cancer                  N/A                      N/A                      UPS of bone              96    Pelvis            2 x 3 x 16           \-      No
  18/F/63               Cervical cancer                  N/A                      N/A                      OSA/Osteoblastic         148   Pelvis            9 x 12 x 16          \-      Resection/M
  19/F/34               Glioma                           N/A                      N/A                      OSA/Osteoblastic         264   Skull             2 x 4 x 6            \-      No
  20/F/70               Breast cancer                    N/A                      N/A                      UPS of bone              408   Sternum           3 x 4 x 4            \-      Resection/W
  21/F/57               Breast cancer                    N/A                      N/A                      OSA/Chondroblastic       156   Rib               13.1 x 13.2 x 14.8   \-      Resection/W
  22M/74                Squamous cell carcinoma          66                       No                       OSA/Fibroblastic         227   Mandible          1 x 1.1 x 1.3        \-      Resection/W
  23/M/43               Liposarcoma                      N/A                      No                       OSA/Osteoblastic         156   Femur             2 x 2.3 x 3.7        \+      Resection/W
  Soft tissue sarcoma                                                                                                                                                                    
  1/F/27                Retinoblastoma                   40/20                    No                       RMS/Embryonal            319   Ethmoid sinus     4.5 x 2.5 x 4        \-      Resection/W
  2/M/47                Hypopharangeal cancer            72                       CDDP, 5-FU               UPS                      145   Neck              6 x 6 x 4            \-      Resection/W
  3/F/68                Uterine cancer                   50.4                     No                       Angiosarcoma             121   Abdominal wall    5 x 3.5 x 1          \-      Resection/W
  4/F/53                Uterine cervical cancer          N/A                      No                       Fibrosarcoma             144   Buttock           14.9 x 12.8 x 7      \-      Resection/M
  5/F/72                Breast cancer                    50                       Yes                      Fibrosarcoma             46    Chest wall        7 x 6 x 3            \-      Resection/W
  6/M/32                Hemangioendothelioma             N/A                      No                       Fibrosarcoma             383   Chest wall        5.7 x 4.5 x 5        \-      ResectionW
  7/F/65                Uterine cancer                   50                       No                       Angiosarcoma             75    Abdominal wall    3 x 3 x 1            \-      Resection/I
  8/M/32                Retinoblastoma                   40/20                    No                       UPS                      370   Ethomoid sinus    1 x 1 x 1            \-      Resection/W
  9/M/73                Tongue carcinoma                 40.8/17                  No                       UPS                      503   Chin              4 x 3 x 2.2          \-      Resection/W
  10/F/75               Breast cancer                    50/25                    No                       Fibrosarcoma             443   Chest wall        8.7 x 3.7 x 7        \-      No
  11/F/42               Lymphoma of bone                 12/6                     ADM, BHAC, 6-MP          UPS                      321   Head              6.5 x 4.4 x 5.5      \-      Resection/W
  12/M/25               Retinoblastoma                   46/23                    CDDP, Thiotepa           RMS                      295   Orbital cavity    3.6 x 2.2 x 3.5      \-      Resection/I
  13/F/63               Uterine cervical cancer          30                       Yes                      UPS                      177   Abdominal wall    11 x 9 x 7.5         \-      Resection/W
  14/M/13               Retinoblastoma                   40                       Yes                      UPS                      160   Accessory sinus   4 x 3.2 x 1.8        \-      Resection/W
  15/M/70               Esophageal cancer                30                       Yes                      Myxofibrosarcoma         167   Back              8 x 5 x 8            \-      Resection/I
  16/F/61               Breast cancer                    50/25                    Epirubicin, CDDP, 5-FU   Synovial sarcoma         50    Shoulder          6 x 8 x 6            \+      Amputation/W
  17/F/61               Breast cancer                    N/A                      No                       Sarcoma, NOS             228   Neck              2 x 4 x 5            \-      Resection/W
  18/F/80               Cervical cancer                  N/A                      No-                      Sarcoma, NOS             444   Pelvis            5 x 7 x 8            \+      No
  19/F/43               Rectal cancer                    63                       Yes                      UPS                      57    Buttock           1.3 x 2.1 x 2.5      \-      Resection/W
  20/F/56               Breast cancer                    N/A                      Yes                      OSA/Extraskeletal        N/A   Shoulder          6.5 x 7.5 x 10.5     ~~-~~   LSS/W

GCT Giant cell tumor, RTx Radiotherapy, Frx Fraction, N/A Not applicable, TGF Transforming growth factor, CBDCA carboplatin, CDDP Cisplatin, 5-FU 5-fluorouracil, ADM Adriamycin, BHAC, Behenoyl cytosine arabinoside, 6-MP 6-mercaptopurine, OSA Osteosarcoma, UPS Undifferentiated pleomorphic sarcoma, RMS Rhabdomyosarcoma, NOS Not otherwise specified, W Wide, LSS Limb-sparing surgery, M Marginal, I Intralesional

The median follow-up periods were 25.5 months (range, 1 to 167 months) in all patients and 33.5 months (range, 5 to 167 months) in 18 survivors. The 5-year MFSR and OSR were 26.3% and 34.4%. The differences in both these survival rates between bone and soft tissue sarcomas were not significant (p = 0.389, and 0.313) ([Fig 1](#pone.0204927.g001){ref-type="fig"}).

![Kaplan-Meier survival curves.\
Kaplan-Meier curves for (A) metastasis-free and (B) overall survivals in the bone and soft tissue post-radiation sarcomas.](pone.0204927.g001){#pone.0204927.g001}

Bone sarcomas {#sec005}
-------------

PRSs of the bone were observed in 17 females and six males with a median age of 60 years (range, 25--78 years). The median main length and volume of the tumors were 8.5 cm (range, 1.3--22 cm) and 117.17 cm^3^ (range, 0.75--1338.47 cm^3^), respectively. Common primary lesions were cancer of the female genital system and breast carcinoma. The most common location and pathologic diagnosis were the pelvis (10) and osteosarcoma (18). All bone sarcomas were high-grade. Four patients had undergone chemotherapy for the primary lesion. In eight patients, it could not be identified whether chemotherapy was administered. The median latency period was 215.5 months (range, 96--408 months) in 18 cases for whom data was available. Fifteen patients underwent surgical treatment for their sarcoma; surgical margins were wide in 14 patients and marginal in one patient. Among eight patients who did not undergo surgery, the median age was 51.5 years (range, 25--76 years), and none of them had distant metastasis at presentation. Among them, six patients had lesions in the pelvis and two patients had lesions in the skull.

The median follow-up periods were 26 months (range, 1 to 135 months) in all 23 patients and 35 months (range, 5 to 135 months) in 11 survivors. The 5-year MFSR and OSR were 14.5% and 16.6%. Prognostic factor analyses of MFSR and OSR are summarized in [Table 2](#pone.0204927.t002){ref-type="table"}. The difference in MFSR according to age (≥60 years vs \<60 years) approached statistical significance (p = 0.070). The differences in OSR depending on age (≥60 years versus \<60 years), main length (≥5 cm versus \<5 cm), and achieving a wide resection (yes versus no) were also insignificant; however, they showed interesting trends ([Fig 2](#pone.0204927.g002){ref-type="fig"}).

![Kaplan-Meier survival curves in univariate analyses for the bone post-radiation sarcoma.\
Kaplan-Meier curves for (A) metastasis-free survival according to age, and for overall survivals according to (B) age, (C) main length and (D) surgical margin.](pone.0204927.g002){#pone.0204927.g002}

10.1371/journal.pone.0204927.t002

###### Prognostic factor analyses of OSR and MFSR in patients with post-radiation bone sarcoma.

![](pone.0204927.t002){#pone.0204927.t002g}

  Factors              Univariate analysis                                     
  -------------------- --------------------- ----------- ------ ------- ------ -------
  Age                  \< 60 years           11 (47.8)   0      0.064   0      0.070
                       ≥ 60 years            12 (52.2)   27.3   24.3           
  Gender               Male                  6 (26.1)    37.5   0.188   30.0   0.240
                       Female                17 (73.9)   0      0              
  Length               \< 5 cm               5 (21.7)           0.075          0.142
                       ≥ 5 cm                18 (78.3)   12.5   11.4           
  Initial metastasis   Yes                   4 (17.4)    0      0.980   0      0.690
                       No                    19 (82.6)   28.0   25.8           
  Surgical treatment   Yes                   15 (69.6)   33.3   0.151   25.8   0.324
                       No                    8 (30.4)                          
  Wide margin          Yes                   14 (60.9)   36.4   0.050   27.9   0.132
                       No                    9 (39.1)                          

OSR overall survival rate, MFSR metastasis-free survival rate

Soft tissue sarcomas {#sec006}
--------------------

High-grade PRSs of the soft tissue were identified in 12 females and seven males with a median age of 56 years (range, 13--80 years). The median main length and volume of the tumors were 5.7 cm (range, 1--14.9 cm) and 65.90 cm^3^ (range, 1--698.23 cm^3^), respectively. The most common primary lesion was carcinoma of the female genital system. The most common histologic diagnosis was undifferentiated pleomorphic sarcoma (6). The median radiotherapy dose for the primary tumor was 43.4 Gy (range, 12--72 Gy) in 14 patients for whom data was available. Ten patients were treated by chemotherapy for their primary lesion. The median latency period was 167 months (range, 46--503 months). Eighteen patients had undergone surgery for PRS; surgical margins were wide in 14 patients, marginal in one patient, and intralesional in three patients. An 80-year-old female with distant metastasis at presentation did not undergo surgical resection of pelvic sarcoma with a main length of 8 cm and a volume of 146.44 cm^3^.

The median follow-up periods were 25 months (range, 3--167 months) in all patients and 53 months (range, 13--167 months) in 9 survivors. Local recurrence developed in 5 patients with wide surgical margin. The 5-year MFSR and OSR were 39.1% and 49.6%. Prognostic factor analyses for MFSR and OSR are summarized in [Table 3](#pone.0204927.t003){ref-type="table"}. The differences in MFSR and OSR depending on initial metastasis (yes versus no) were statistically significant (p\<0.001, respectively). The differences in MFSR and OSR according to the surgical treatment (yes versus no) were also significant (p = 0.004 and p = 0.030) ([Fig 3](#pone.0204927.g003){ref-type="fig"}).

![Kaplan-Meier survival curves in univariate analyses for the soft tissue post-radiation sarcoma.\
Kaplan-Meier curves for (A) metastasis-free and (B) overall survivals according to initial metastasis, and for (C) metastasis-free and (D) overall survivals according to surgical treatment.](pone.0204927.g003){#pone.0204927.g003}

10.1371/journal.pone.0204927.t003

###### Prognostic factor analyses of OSR and MFSR in patients with post-radiation soft-tissue sarcoma.

![](pone.0204927.t003){#pone.0204927.t003g}

  Factors                              Univariate analysis                                                                            
  ------------------------------------ --------------------- ----------- ------ ---------------------------------------------- ------ ----------------------------------------------
  Age                                  \< 60 years           10 (52.6)   57.1   0.154                                          38.6   0.343
                                       ≥ 60 years            9 (47.4)    44.4   44.4                                                  
  Gender                               Male                  7 (36.8)    53.3   0.293                                                 0.849
                                       Female                12 (63.2)   44.4   46.7                                                  
  Length                               \< 5 cm               7 (36.8)    57.1   0.469                                                 0.614
                                       ≥ 5 cm                12 (63.2)   46.9   41.7                                                  
  Initial metastasis                   Yes                   2 (10.5)    0      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0      \<0.001[\*](#t003fn002){ref-type="table-fn"}
                                       No                    17 (89.5)   55.5   43.7                                                  
  Surgical treatment                   Yes                   18 (94.7)   52.4   0.030[\*](#t003fn002){ref-type="table-fn"}     41.3   0.004[\*](#t003fn002){ref-type="table-fn"}
                                       No                    1 (5.3)     0      0                                                     
  Wide margin                          Yes                   14 (73.7)   54.4   0.545                                          40.8   0.685
                                       No                    5 (26.3)    30.0   30.0                                                  
  Age at diagnosis of primary lesion   \< 20 years           6 (31.6)    60.0   0.343                                          40.0   0.410
                                       ≥ 20 years            13 (68.4)   47.5   43.1                                                  
  Previous chemotherapy                Yes                   10 (52.6)   61.7   0.164                                          54.9   0.151
                                       No                    9 (47.4)    35.6   18.5                                                  
  Latency period                       \< 15 years           11 (57.9)   60.6   0.669                                          53.0   0.563
                                       ≥ 15 years            8 (42.1)    36.5   18.8                                                  

OSR overall survival rate, MFSR metastasis-free survival rate

\*Statistically significant

Discussion {#sec007}
==========

We conducted this study to understand the current status of PRS in an Asian population and to explore the differences from the existing results of Western researches. Although recent rapid advances in tumor treatment and surveillance have improved the prognosis, comprehension of treatment-related risks seems to be too inadequate to reduce the therapy-related long-term complications, especially in Asia.

A multi-national, multi-institutional retrospective study inevitably has a potential for selection and management bias. Detailed information of some cases was not available. However, given that these diseases are rare and have been reported rarely in an Asian population, these results may be useful. As we have no data on the patients who had received radiation therapy within the same period as this study population, even an approximate risk of PRSs, potentially one of the most important points in an Asian study, could not be estimated.

The age of patients with PRS is determined by the age at radiotherapy for the first cancer and subsequent latency period, and it has been reported to range from five to 86 years \[[@pone.0204927.ref005], [@pone.0204927.ref013]--[@pone.0204927.ref015]\]. Cohort and registry researches have reported that medical radiation treatment increases the risk of subsequent bone sarcoma from approximately two times in adults to more than 100 times in some pediatric populations \[[@pone.0204927.ref016]\]. While previous studies have suggested a difference in susceptibility to radiotherapy between children and adults and an inverse relationship between age at radiation exposure and risk of osteosarcoma development \[[@pone.0204927.ref017], [@pone.0204927.ref018]\], more recent reports have proposed that the risk may increase again in the elderly, which potentially implies that radiation acts as a cancer promoter rather than a cancer initiator \[[@pone.0204927.ref019], [@pone.0204927.ref020]\]. However in this study, the details of children and adult patients were not analyzed separately. Age at radiotherapy might also affect the latency period \[[@pone.0204927.ref012], [@pone.0204927.ref021]--[@pone.0204927.ref023]\]. Previous literatures have reported that mean latency periods for post-radiation soft tissue sarcoma and bone sarcoma range from 6 to 18 years \[[@pone.0204927.ref021], [@pone.0204927.ref024]--[@pone.0204927.ref028]\] and from 4 to 17 years \[[@pone.0204927.ref011], [@pone.0204927.ref021], [@pone.0204927.ref022], [@pone.0204927.ref028]--[@pone.0204927.ref033]\], respectively. However, they also showed a wide range of latency periods \[[@pone.0204927.ref034]\], and a case developing after 65 years post-radiation has been reported \[[@pone.0204927.ref005]\]. While it is still controversial whether the latency periods for post-radiation soft tissue sarcoma and bone sarcoma are significantly different, some studies have demonstrated that the period may be longer in bone sarcoma \[[@pone.0204927.ref012]\], and this study did not show a statistical difference. Several reports have shown that the latency period seemed to be inversely associated with the radiation dose \[[@pone.0204927.ref014], [@pone.0204927.ref035]\]; however, the others reports presented contrary data \[[@pone.0204927.ref021], [@pone.0204927.ref026], [@pone.0204927.ref036], [@pone.0204927.ref037]\]. A study \[[@pone.0204927.ref004]\] showed that the latency period in radiation-associated chondrosarcoma was longer than that in osteosarcoma, and it suggested that this may be because chondrosarcoma typically shows slower growth with less metastasis than osteosarcoma. Additional enlightenment on the expected latency period for individual conditions may lead to the development of an efficient strategy for patient education and surveillance and may result in an expeditious differential diagnosis \[[@pone.0204927.ref005], [@pone.0204927.ref015]\].

Previous researches have shown that common primary diagnoses of PRSs were soft tissue neoplasms, such as breast cancer \[[@pone.0204927.ref003], [@pone.0204927.ref011]--[@pone.0204927.ref015], [@pone.0204927.ref026], [@pone.0204927.ref029]--[@pone.0204927.ref033], [@pone.0204927.ref037]--[@pone.0204927.ref042]\], lymphoma \[[@pone.0204927.ref012]--[@pone.0204927.ref014], [@pone.0204927.ref021], [@pone.0204927.ref026], [@pone.0204927.ref029], [@pone.0204927.ref030], [@pone.0204927.ref032], [@pone.0204927.ref039], [@pone.0204927.ref040], [@pone.0204927.ref043]\], genitourinary cancer \[[@pone.0204927.ref013], [@pone.0204927.ref014], [@pone.0204927.ref021], [@pone.0204927.ref026], [@pone.0204927.ref027], [@pone.0204927.ref029]--[@pone.0204927.ref033], [@pone.0204927.ref038], [@pone.0204927.ref040]\], and head and neck cancer \[[@pone.0204927.ref005]\]. Particularly with respect to breast carcinoma, the first case arising in the chest wall after radiation was reported in 1976 \[[@pone.0204927.ref044]\]. This study distinctively included five cases with retinoblastoma. A recent study has revealed a difference in standardized incidence ratios for subsequent PRS according to the type of first cancer \[[@pone.0204927.ref045]\].

As PRS is often locally aggressive, and therefore, it has already advanced and not resectable or may metastasize at initial diagnosis, it is related to a poor overall prognosis \[[@pone.0204927.ref005], [@pone.0204927.ref007], [@pone.0204927.ref015], [@pone.0204927.ref028], [@pone.0204927.ref046]\]. Local recurrence rates ranged from 17% to 68% \[[@pone.0204927.ref015], [@pone.0204927.ref028], [@pone.0204927.ref047], [@pone.0204927.ref048]\], and 5-year survival rates ranged from 11% to 48% \[[@pone.0204927.ref006], [@pone.0204927.ref015], [@pone.0204927.ref024], [@pone.0204927.ref028], [@pone.0204927.ref046]--[@pone.0204927.ref053]\]. In this study, initial metastasis was a univariate prognostic factor for OSR and MFSR for soft tissue PRS as observed in the previous literature \[[@pone.0204927.ref054]\]. Prognosis was reported to be associated with site of the lesion \[[@pone.0204927.ref005], [@pone.0204927.ref055]\], and the immunocompromising effect and altered regional environment after the previous treatment for primary disease \[[@pone.0204927.ref023]\]. PRS most commonly arises at unfavorable sites, such as central trunk, or pelvic and shoulder girdles \[[@pone.0204927.ref005], [@pone.0204927.ref015], [@pone.0204927.ref026], [@pone.0204927.ref039]\]; therefore, the diagnosis is delayed \[[@pone.0204927.ref023], [@pone.0204927.ref039]\], and curative resection might be difficult to achieve \[[@pone.0204927.ref005], [@pone.0204927.ref015]\]. In this study, a wide surgical margin was almost found to be a prognostic factor for bone PRS as it was a significant factor in previous researches \[[@pone.0204927.ref054], [@pone.0204927.ref056]\]. Moreover, circumjacent abundant vascularity and lymphatics in the girdle region might facilitate metastasis and result in worse prognosis compared to the extremity lesions \[[@pone.0204927.ref057]\]. Immunosuppression, lymphatic obstruction, vascular insufficiency, or fibrosis could also shelter the malignant cells from the immune mechanism \[[@pone.0204927.ref023]\], which may cause the secondary lesions to be poorly differentiated and aggressive \[[@pone.0204927.ref039]\]. Other prognostic factors were also reported in previous literatures \[[@pone.0204927.ref046], [@pone.0204927.ref049], [@pone.0204927.ref054], [@pone.0204927.ref056]\]. Older age was reported as a prognostic factor for poor survival \[[@pone.0204927.ref056]\] and in this study it was almost found to be a univariate predictor of MFSR and OSR in bone PRS. While a previous report demonstrated that survival difference between bone and soft tissue PRSs was not significant \[[@pone.0204927.ref049]\], another recent report showed that the 5-year survival rates were 52% for bone PRS and 15% for soft tissue PRS, and the difference was significant in univariate analysis \[[@pone.0204927.ref028]\]. On the contrary, the OSR and MFSR in patients with soft tissue PRS was even higher in this study. Lager lesion was also proposed to be a survival predictor in previous reports \[[@pone.0204927.ref046], [@pone.0204927.ref054]\] and it was almost analyzed to be a univariate prognostic factor for OSR in patients with the bone PRS in this study. Although most of the patients who had not undergone surgery in this study did not have initial metastasis, the median age was high, the tumors were bone sarcomas located in difficult-to-access areas such as the pelvis and skull, and the median lesion size was large. In addition, histologic type and grade and symptom duration were suggested to be associated with prognosis \[[@pone.0204927.ref046], [@pone.0204927.ref056]\].

Although PRS management should be discussed in a multi-disciplinary setting, achieving wide surgical margins may be a unique clinical goal in most cases. PRSs are radio-resistant \[[@pone.0204927.ref023], [@pone.0204927.ref039], [@pone.0204927.ref046], [@pone.0204927.ref049]\], and the tissues surrounding these tumors have already been irradiated. Fibrosis due to irradiation also diminishes the chemotherapy effect \[[@pone.0204927.ref013], [@pone.0204927.ref023], [@pone.0204927.ref024], [@pone.0204927.ref039], [@pone.0204927.ref050], [@pone.0204927.ref051], [@pone.0204927.ref056], [@pone.0204927.ref058]\]. Because a considerable proportion of patients are elderly, the balance between potential risks and benefits of systemic therapy should also be reviewed \[[@pone.0204927.ref015]\]. Previous studies have shown that chemotherapy alone was only a palliative solution and it had no impact on prognosis \[[@pone.0204927.ref012], [@pone.0204927.ref013], [@pone.0204927.ref015], [@pone.0204927.ref023], [@pone.0204927.ref024], [@pone.0204927.ref039], [@pone.0204927.ref049]--[@pone.0204927.ref051]\], and that postoperative chemotherapy had no association with higher survival rate \[[@pone.0204927.ref013], [@pone.0204927.ref023], [@pone.0204927.ref024], [@pone.0204927.ref039], [@pone.0204927.ref050], [@pone.0204927.ref051], [@pone.0204927.ref058]\]. A previous study recommended reserving complete excision of the field denatured by radiation based on the concept that recurrence would develop in deep tissues or at margins of a generous resection \[[@pone.0204927.ref015]\]. However, we currently believe that it would be more effective to excise as much surrounding fibrotic denatured tissues as possible around PRS for delivery of chemotherapeutic agents to the target and for eliminating the possibility of additional malignant transformation. A close follow-up is understandably required for tendency for high local recurrence \[[@pone.0204927.ref015]\].

Although we conducted a multi-national, multi-institutional study in which 10 tertiary centers from four Asian nations had participated, the number of cases collected was less than expected despite the strict inclusion and exclusion criteria of this study. Furthermore, as patients with malignancy such as breast cancer normally have favorable prognosis, or those currently receiving radiation treatment have improved prognosis, they survived for a long period adequate enough to experience the oncogenic effects of radiation \[[@pone.0204927.ref017], [@pone.0204927.ref021], [@pone.0204927.ref027], [@pone.0204927.ref037], [@pone.0204927.ref038], [@pone.0204927.ref042]\], with aggravation of the relative risk with increasing time \[[@pone.0204927.ref037]\]. It may be because of the long latency period, a clinically short follow-up period, inadequate medical records without detailed previous medical history, and lack of awareness regarding PRS resulting in failure to recognize and report cases \[[@pone.0204927.ref005]\]. There could be still a small number of long-term survivors, because the Asian medical environment is very heterogeneous despite well-developed health services in few countries \[[@pone.0204927.ref008]\]. Looking on the brighter side, recent high-precision radiotherapy, which can increase the radiation dose delivered into tumors while maximizing the protection of normal tissues as much as possible, could be a reason \[[@pone.0204927.ref059]\].

Conclusions {#sec008}
===========

To the best of our knowledge, this study is the largest review on PRS in an Asian population although it failed to find ethnic differences. Radiotherapists should avoid unnecessary radiation exposure. Early recognition through long-term surveillance and a high degree of awareness regarding PRS are current unique keys to optimal and timely management by a multidisciplinary team. Clinicians should be concerned about this entity and they should make efforts to understand the real status of PRS.
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